Detalhe da pesquisa
1.
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
Blood
; 142(23): 1960-1971, 2023 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37647654
2.
Evaluation of T-cell clonality by anti-TRBC1 antibody-based flow cytometry and correlation with T-cell receptor sequencing.
Br J Haematol
; 204(3): 910-920, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38098188
3.
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Lancet
; 402(10399): 373-385, 2023 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37311468
4.
Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.
Am J Hematol
; 97(8): 1013-1022, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35560061
5.
Immunophenotypic characterisation of acute myeloid leukaemia with UBTF tandem duplications.
Br J Haematol
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38544472
6.
Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome.
Blood
; 140(22): 2407-2411, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35960851
7.
A novel ATRX variant with splicing consequences in myelodysplastic syndrome with acquired alpha thalassaemia.
Br J Haematol
; 200(1): e13-e16, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36278851
8.
Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
Br J Haematol
; 202(4): 893-896, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37280781
9.
Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.
Antimicrob Agents Chemother
; 61(11)2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28807922
10.
Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies.
Antimicrob Agents Chemother
; 59(9): 5463-9, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26124158
11.
Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial.
J Antimicrob Chemother
; 70(8): 2369-75, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25953805
12.
Observations from a national sample exchange program for molecular haematology testing.
Pathology
; 56(4): 540-547, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38413254
13.
Reporting bone marrow biopsies for myelodysplastic neoplasms and acute myeloid leukaemia incorporating WHO 5th edition and ICC 2022 classification systems: ALLG/RCPA joint committee consensus recommendations.
Pathology
; 56(4): 459-467, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38580613
14.
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).
J Clin Oncol
; : JCO2301599, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38427924
15.
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.
Blood Adv
; 8(2): 343-352, 2024 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38039513
16.
How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?
Blood Cancer J
; 14(1): 54, 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38531863
17.
Cellular distribution of IDH mutations in AML during morphologic remission.
Leuk Res
; 124: 106993, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36459762
18.
Persistence of UBTF tandem duplications in remission in acute myeloid leukaemia.
EJHaem
; 4(4): 1105-1109, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-38024622
19.
Apparent 'JAK2-negative' polycythaemia vera due to compound mutations in exon 14.
Br J Haematol
; 178(2): 333-336, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27136492
20.
Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia.
Blood Adv
; 6(13): 3879-3883, 2022 07 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35511730